07:44 AM EST, 01/22/2025 (MT Newswires) -- ImmunoPrecise Antibodies' ( IPA ) shares climbed by nearly 80% in premarket trading Wednesday after the company said it has developed a new class of GLP-1 therapies to treat diabetes using its LENS AI artificial intelligence platform.

The company said the new therapies were developed through the platform's "rapid sequence generation process."

The new class of GLP-1 therapies are under evaluation for transdermal delivery as a potential alternative to injections, ImmunoPrecise Antibodies ( IPA ) said.